Arkolith/Insider Trading/ZYME/Form 4

Moore Paul Andrew

Chief Scientific OfficerZymeworks Inc. (ZYME) · full profile →Form 4 · filed Jan 12, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$217K
Net Open-Market Flow
-$217K
Transactions
6
2 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Option exercise(M)18K—$058K
Jan 12, 2026Sell(S)10K$22.67$217K48K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Grant(A)47K—$047K
Jan 12, 2026Grant(A)66K—$066K
Jan 12, 2026Grant(A)70K—$070K
Jan 12, 2026Option exercise(M)18K—$035K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-010834) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Zymeworks Inc.

Build

Ask your agent about ZYME insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001193125-26-010834"
Ask your agent
Use Arkolith to summarize insider buying and selling at Zymeworks Inc.
over the last 90 days and cite the filings.